• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Sumitomo Pharma (TSE:4506) Gains Attention On Ulotaront, Is The Stock Cheap?

    Simply Wall St·10/09/2026 21:25:20
    语音播报

    Recent attention on the schizophrenia treatment market has put Sumitomo Pharma (TSE:4506) in focus, as its investigational therapy Ulotaront, developed with Otsuka Pharmaceuticals, is highlighted as a potential new option for patients.

    Against that backdrop, Sumitomo Pharma’s 90-day share price return of 13.68% and 30-day gain of 3.01% suggest improving momentum from a lower base, even though the year-to-date share price performance is down 35.33% and the 1-year total shareholder return has declined 12.84%. The 3-year total shareholder return remains very large at about 3.4x.

    Spot emerging opportunities around Sumitomo Pharma’s Ulotaront story by comparing it with other potential breakout healthcare names in our curated list of 9 healthcare AI stocks.

    Sumitomo Pharma now has a high profile drug candidate and a share price that has rebounded from a weaker year. Does that mix of potential and past volatility add up to an appealing valuation today?

    Most Popular Narrative: 23% Undervalued

    The most followed narrative values Sumitomo Pharma at ¥2,071 per share, above the last close of ¥1,591.5. That gap frames Ulotaront and the wider pipeline as central to whether the current discount is justified.

    Ambitious oncology and regenerative medicine programs such as enzomenib, nuvisertib and iPS cell therapies require accelerated clinical activity and shared development with partners. This may lift R&D outlays faster than product contributions, reducing near to medium term earnings leverage.

    See why 1 investors see Sumitomo Pharma as 23% undervalued.

    Under this narrative, analysts apply a 4.996% discount rate and arrive at a fair value that is about 23% above the prevailing market price. That view combines forecasts for revenue growth with an expected decline in profit margins and a higher future P/E multiple to reconcile today’s price with longer term earnings power.

    The same narrative assumes earnings will decline on average over the next 3 years, even as revenue is expected to rise, which places extra weight on how efficiently Sumitomo Pharma can convert its pipeline and restructuring efforts into sustainable profitability. The implied valuation asks investors to weigh a very large recent earnings uplift, helped by one off gains, against forecasts for softer profitability once those items roll off.

    Result: Fair Value of ¥2,071 (UNDERVALUED)

    Still, strong momentum from ORGOVYX and GEMTESA in North America, together with tighter cost control at Sumitomo Pharma, could challenge the idea that the shares trade at a wide discount.

    Find out about the key risks to this Sumitomo Pharma narrative.

    Next Steps

    Mixed messages around Sumitomo Pharma’s valuation and risk profile can be confusing. Investors may wish to move quickly, review the full data set, and weigh both the 3 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond Sumitomo Pharma?

    If you stop with Sumitomo Pharma, you only see part of the opportunity set. Use the Simply Wall Street Screener to quickly surface fresh possibilities aligned with your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.